GenLight Diagnostics, Inc. (GLDI) is assisting in selection and conducting genomic, genetic and molecular diagnostic tests providing to practicing physicians and patients the essential information regarding the individual’s genetic disease profiles and likelihood of failure or cure after applications of existing therapeutic protocols.
 

NEW: We are offering a broad range of proprietary products and services to assist healthy people in understanding the individual's genetic risk of developing common human disorders.

GenLight's Cancer Therapy Outcome Prediction Algorithm

One of the main components of GenLight Diagnostics services entail microarray-based and Q-PCR-based genomic and genetic tests integrating multiple cancer therapy outcome predictor (CTOP) gene signatures designed for cancer therapy outcome prediction and assessment of long-term disease prognosis and patient's survival. This information will be used to stratify patients diagnosed with prostate, breast, lung, or ovarian cancers into sub-groups with statistically distinct clinical outcomes after initial standard therapy: (1) patients with therapy-responsive cancers (patients with high probability of a cure with existing cancer therapies) and (2) patients with therapy-resistant cancers (patients with high probability of therapy failure and disease relapse after application of standard therapeutic protocols). This patients' stratification approach has been validated by retrospective analyses of large databases of breast and prostate tumors from patients with known long-term therapy outcomes after treatment in several independent Institutions worldwide. Currently, these tests can be completed using tumor tissue samples. In the future, GenLight Diagnostics will conduct blood and urine tests for diagnosis, prognosis, and therapy outcome prediction. These new assays are being developed by Dr. Glinsky’s lab and will be licensed to GenLight Diagnostics once they are fully developed and validated. Additional algorithms and gene signatures will also be developed and used for diagnosis, risk stratification, and therapy outcome predictions for other cancers, such as pancreatic and colon cancers.

We will help to measure, calculate, evaluate, and understand your individual genetic risk of developing common human disorders. If desired, we will be able to perform this analysis for all your family members, including your children and your future offspring. We will assess your individual genetic risk factors for developing the following major common human disorders:    

Alzheimer’s disease (AD)

Autism Spectrum Disorders (ASD)

Bipolar disease (BD)

Rheumatoid arthritis (RA)

Coronary artery disease (CAD)

Crohn's disease (CD)

Type 1 diabetes (T1D)

Type 2 diabetes (T2D)

Obesity (OB)

Hypertension (HT)

Ankylosing spondylitis (AS)

Graves' disease (autoimmune thyroid disease; AITD);

Multiple sclerosis (MS);

Breast cancer (BC);

Prostate cancer (PC);

Lung cancer (LC);

Ovarian cancer (OC);

Melanoma (MEL);

Parkinson’s disease (PD);

Systemic lupus erythematosus (SLE)

Vitiligo (VIT)

Huntington’s disease (HD)

Ulcerative colitis (UC)

Multiple autoimmune diseases (MAD)

 

GenLight Technologies Corporation, Inc. (GLTCI)